At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
Belnacasan +1 moredrug
Likely dose
Placebo 0mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Proof of Concept, Randomized, Double-blind, Placebo-controlled Trial of Orally Administered Belnacasan Tablets for the Treatment of Mild to Moderate COVID-19
In Brief
A Phase 2 clinical trial evaluating Belnacasan and Placebo for COVID-19. Completed, enrolled 40 participants across 2 sites.
Detailed Summary
The purpose of this trial is to assess the safety, tolerability and treatment effect of the orally administered Caspase-1 inhibitor, belnacasan, for the treatment of patients with mild to moderate COVID-19 and to generate proof of concept for future trials.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartDec 2021
First PostedDec 2021
Primary CompletionJul 2022
Study CompletionOct 2022
TodayJul 2026
First PostedDec 20, 2021
Enrollment StartDec 14, 2021
Primary CompletionJul 18, 2022
Study CompletionOct 11, 2022
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 4.5 years ago
Interventions
Belnacasandrug
Oral administration
Placebodrug
Tablet containing 0mg of API